Atrial Fibrillation
Friday, July 26th, 2013
The American College of Cardiology (ACC): 7/23/13 Last year the ACC launched the Anticoagulation Initiative, a comprehensive quality effort to help facilitate a greater understanding of treatments and practice patterns in patients with atrial fibrillation, particularly given an increasing number of new anticoagulant treatment options entering the marketplace. The initiative is a multidisciplinary effort that addresses gaps […]
Atrial Fibrillation
Friday, July 26th, 2013
CIRCEP: July 22, 2013 Background—The ACE deletion allele, ACE D, is associated with increased cardiac ACE activity, cardiac fibrosis and adverse outcomes in cardiovascular disease and has been linked with failure of anti-AF drug treatment. This study tested the hypothesis that the angiotensin-converting enzyme gene (ACE) insertion/deletion (I/D) polymorphism associates with atrial fibrillation (AF) recurrence after catheter ablation. […]
Atrial Fibrillation
Friday, July 26th, 2013
CIRCEP: July 21, 2013 Background—Low resting heart rate (HR) has been associated with atrial fibrillation (AF) in athletes. We aimed to study if low HR at rest or during exercise testing was a predictor of AF in initially healthy middle-aged men. Methods and Results—A total of 2014 healthy Norwegian men participated in a prospective cardiovascular survey […]
Atrial Fibrillation
Friday, July 26th, 2013
J Am Heart Assoc: July 18, 2013 Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry ackground The prevalence of atrial fibrillation (AF) continues to increase; however, there are limited data describing the division of care among practitioners in the community and whether care differs depending on provider […]
Atrial Fibrillation
Friday, July 26th, 2013
American College of Cardiology Foundation: June 27, 2013 At last! For patients and doctors weary of monitoring INRs, a new host of long-anticipated oral anticoagulant therapies have joined warfarin and aspirin as excellent options in reducing the associated risk of thromboembolic stroke in atrial fibrillation. But which option is best? That, of course, depends on the […]
Clinical Trials
Friday, July 26th, 2013
STROKEAHA: July 25, 2013 Background and Purpose—Acute treatments specifically for intracerebral hemorrhage (ICH) are being sought in randomized controlled trials. The treatment effect sizes in ongoing and future trials are likely to be small, necessitating large sample sizes. Methods—We searched online trial registries for randomized controlled trials investigating an acute treatment for ICH. For the trials […]
Clinical Trials
Friday, July 26th, 2013
Wiley: JUL 23, 2013 Recent publications describing the sobering global increase in stroke mortality and global life years lost due to stroke despite improvements in developed countries have drawn focus on the severe impact of stroke in the developing world. At the same time, three recent interventional trials that failed to demonstrate an important role […]
Clinical Trials
Friday, July 26th, 2013
STROKEAHA: July 18, 2013 Background and Purpose—Unilateral and bilateral training protocols for upper limb rehabilitation after stroke represent conceptually contrasting approaches with the same ultimate goal. In a randomized controlled trial, we compared the merits of modified constraint-induced movement therapy, modified bilateral arm training with rhythmic auditory cueing, and a dose-matched conventional treatment. Modified constraint-induced movement […]
Clinical Trials
Friday, July 26th, 2013
STROKEAHA: July 2, 2013 As the nation’s primary supporter of basic and clinical stroke research, the National Institute of Neurological Disorders and Stroke (NINDS) strives to pursue the most pressing and promising scientific opportunities. During the past decade, NINDS has led a stroke planning effort performed by the Stroke Progress Review Group (PRG), an external group […]
Clinical Trials
Friday, July 26th, 2013
STROKEAHA: June 20, 2013 Background and Purpose—In the German Multicenter Erythropoietin (EPO) Stroke Trial, patients not receiving thrombolysis most likely benefited from EPO on clinical recovery, whereas a combination of rtPA and EPO was associated with increased mortality. We investigated whether the combination of rtPA and EPO increased release of the endogenous NO synthase inhibitor asymmetric […]
